About me
Chris DeRespino serves as chief business officer at 3T Biosciences, an industry leader in pHLA targeting biologics and target discovery. In this role, Mr. DeRespino is responsible for leading G&A functions including business development, finance & human resources. Previously, Mr. DeRespino was CBO and acting chief financial officer at Adverum Biotechnologies, and spent nearly eight years at Amgen, most recently as executive director of business development. Prior to Amgen, he was director, asset acquisition/business development at Onyx Pharmaceuticals, which Amgen acquired for $10.4 billion, and served at Pfizer as director of business development evaluation and strategy. Earlier in his career, Chris worked in management consulting. Mr. DeRespino earned his MBA from the Leonard N. Stern School of Business at New York University, and a B.S.E. in biomedical engineering from The Johns Hopkins University.
